We are live on ! Find out more
BLRX

BioLineRX
BLRX

25 hedge funds and large institutions have $26.9M invested in BioLineRX in 2015 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 1

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

194% more capital invested

Capital invested by funds: $9.16M → $26.9M (+$17.8M)

67% more funds holding

Funds holding: 15 → 25 (+10)

Holders
25
Holders Change
+10
Holders Change %
+66.67%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$6.36M
2
SM
Senvest Management
New York
+$2.15M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.54M
4
Millennium Management
Millennium Management
New York
+$896K
5
Deutsche Bank
Deutsche Bank
Germany
+$663K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$378K
2
Renaissance Technologies
Renaissance Technologies
New York
-$44K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$7.02M +$2.15M +1,746 +46%
BC
2
Broadfin Capital
New York
$6.54M +$6.36M +5,167 New
BI
3
BVF Inc
California
$3.17M – – –
O
4
OrbiMed
New York
$2.4M – – –
Alyeska Investment Group
5
Alyeska Investment Group
Illinois
$1.58M +$1.54M +1,250 New
SM
6
Sabby Management
Florida
$1.57M -$378K -307 -20%
Deutsche Bank
7
Deutsche Bank
Germany
$1.36M +$663K +539 +100%
Millennium Management
8
Millennium Management
New York
$922K +$896K +728 New
Morgan Stanley
9
Morgan Stanley
New York
$725K +$649K +527 +1,171%
OM
10
Opaleye Management
Massachusetts
$528K – – –
SFM
11
Sphera Funds Management
Israel
$408K +$396K +322 New
MC
12
Menta Capital
California
$161K +$156K +127 New
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$145K +$142K +115 New
BCA
14
Benchmark Capital Advisors
New York
$84K – – –
NFG
15
Next Financial Group
Texas
$79K +$18.5K +15 +31%
VKH
16
Virtu KCG Holdings
New York
$62K +$60.3K +49 New
Jane Street
17
Jane Street
New York
$39K +$36.9K +30 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$38K – – –
CCB
19
Cutter & Co Brokerage
Missouri
$32K +$9.85K +8 +47%
KA
20
Kovack Advisors
Florida
$30K +$29.5K +24 New
PNC Financial Services Group
21
PNC Financial Services Group
Pennsylvania
$21K – – –
UBS Group
22
UBS Group
Switzerland
$17K +$16K +13 New
Citigroup
23
Citigroup
New York
$11K +$9.85K +8 New
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$4K – – –
Wells Fargo
25
Wells Fargo
California
$2K – – –
1
2

BLRX Hedge Fund Activity: Q1 2015 in Review

25 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2015, worth a combined $26.9M — up 194% from $9.16M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new BLRX positions and 1 closed out — a net gain of 10 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $6.36M. The largest seller was Sabby Management, cutting an estimated $378K.

  • 25 institutional investors held BioLineRX (BLRX) as of Q1 2015, up from 15 in Q4 2014.
  • Funds reported $26.9M of BioLineRX stock for Q1 2015, up 194% quarter-over-quarter.
  • 11 funds opened new BioLineRX positions in Q1 2015 and 1 closed out, a net change of +10 holders.
  • The largest BioLineRX buyer in Q1 2015 was Broadfin Capital, an estimated $6.36M added.
  • The largest BioLineRX seller in Q1 2015 was Sabby Management, an estimated $378K sold.

Based on aggregated 13F filings for Q1 2015.